Delivery Order SPE2DB22D2007-SPE2DB25FJ3PX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,386.04 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 15, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,790.80 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, with completion targeted for October 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the contractor's pharmaceutical supply services to the federal government. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vial (5ML) on July 25, 2025, with an ultimate completion date of August 15, 2025. This is a non-set-aside contract, competitively awarded to support federal medical procurement needs. The product will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office and primary distribution operations. This delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,744.80 on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL vials (5mL) to support federal medical procurement needs. The award is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 20, 2025, and is funded through the Defense Logistics Agency's Medical Supply Chain division. This contract represents...
- The Defense Logistics Agency awarded a delivery order valued at $2,079.06 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of September 29, 2025. This is a firm fixed-price, non-set-aside contract issued on September 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vial (5mL) pharmaceutical products, valued at $21,489.72 under a firm fixed-price contract type. The award was made on September 3, 2025, with an ultimate completion date of September 24, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office...
- The Defense Logistics Agency awarded a $17,908 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Hyperrab 300 Unit/mL vials (5mL). This competitively awarded, non-set-aside contract reflects firm fixed pricing and is scheduled for completion by June 30, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems....
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide HYPERRAB 300 UNIT/ML VIAL ML, a specialty pharmaceutical product, with a ceiling value of $2,605.33 and a performance period through April 15, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded solely to AmerisourceBergen Drug Corp by DLA,...
- The Defense Logistics Agency awarded a $16,632.48 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,465.10 on August 19, 2025, for HYPERRAB 300 Unit/mL vials. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania, and an ultimate completion date of September 10, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3PXDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,079.06 for HYPERRAB 300 Unit/ML Vial on August 4, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order represents a small-value pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for the federal government, particularly supporting the Defense Logistics Agency's medical supply chain and military healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which serves as the underlying vehicle enabling the company to supply pharmaceutical products and medical supplies globally. This HYPERRAB delivery order reflects AmerisourceBergen's ongoing role in fulfilling specialized pharmaceutical requirements for federal medical procurement through competitively awarded contracts with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/4/25 |